SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.72 |
| Enterprise Value ($M) | -3.78 |
| Book Value ($M) | 4.71 |
| Book Value / Share | 5.20 |
| Price / Book | 0.58 |
| NCAV ($M) | 4.65 |
| NCAV / Share | 5.14 |
| Price / NCAV | 0.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.19 |
| Return on Assets (ROA) | -1.02 |
| Return on Equity (ROE) | -1.59 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.43 |
| Current Ratio | 3.43 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 6.57 |
| Assets | 6.62 |
| Liabilities | 1.91 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -7.98 |
| Net Income | -15.04 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -18.32 |
| Cash from Investing | -0.02 |
| Cash from Financing | 12.85 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,664 | 10,412 | 15.98 | |
| 10,190 | 113,977 | 8.94 | |
| 2,372 | 78,853 | 3.01 | |
| 9,056 | 47,422 | 19.10 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| QLGN – Qualigen Therapeutics, Inc. | QTTB – Q32 Bio Inc. |
| RENB – Renovaro Inc. | RGC – Regencell Bioscience Holdings Limited |
| RGLS – Regulus Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io